Madopar Depot (Benserazide Hydrochloride, Levodopa)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine, the neurotransmitter deficient in Parkinson's disease. Benserazide inhibits the enzyme dopa decarboxylase in peripheral tissues, preventing premature conversion of levodopa outside the brain, thereby increasing the amount that reaches central nervous system sites where it can be transformed into dopamine.

The specific dose of Madopar Depot is individualized by the prescribing clinician based on the patient’s disease severity, response to therapy, and tolerability. Dosage adjustments are made during treatment to achieve optimal symptom control while minimizing side effects. Patients should follow the exact regimen provided by their healthcare professional.

Safety data for Madopar Depot in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To request Madopar Depot, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will ask for trade or institutional credentials. After verification, the team provides pricing, availability, shipping details (including any temperature controls), and necessary import documentation.

Madopar Depot combines levodopa with benserazide, a peripheral dopa decarboxylase inhibitor, which enhances central dopamine availability compared with levodopa alone. Compared with dopamine agonists, it provides more direct dopamine replacement but may have a higher risk of motor complications such as dyskinesia. Choice of therapy depends on individual patient factors, disease stage, and tolerability.

Madopar Depot should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed. Do not store in a refrigerator or freezer unless specifically instructed by the manufacturer.

Madopar Depot is taken orally, usually with a glass of water. It may be administered with or without food, but taking it with a light meal can reduce gastrointestinal upset. The tablet should be swallowed whole; it should not be crushed, chewed, or divided unless directed by a healthcare professional.

Serious risks include neuroleptic malignant syndrome, severe depression or suicidal thoughts, and cardiac arrhythmias. Patients should be monitored for sudden changes in mood, fever, muscle rigidity, or irregular heartbeats. Prompt medical attention is required if any of these severe adverse events occur.

Madopar Depot is contraindicated in patients with known hypersensitivity to levodopa, benserazide, or any excipients in the formulation. It should also be avoided in individuals taking non‑selective monoamine oxidase inhibitors, or those with a history of malignant neuroleptic syndrome. Clinicians must assess each patient’s medical history before initiating therapy.